Utilizing a CDST for Resistant/Refractory CMV in Hematopoietic Cell Transplant Patients

Program Overview

Join Drs. Kotton, Chemaly, and Papanicolaou as they illustrate how to use a new clinical decision support tool (CDST) for resistant or refractory cytomegalovirus (CMV) infection in hematopoietic cell transplant (HCT) patients. They will walk you through a challenging CMV resistant patient case and demonstrate how to enter clinical data into the novel CDST for optimal treatment decision making. Expert panel discussions provide an opportunity for you to learn how to apply the CDST in practice and incorporate a new therapy, maribavir, into the care of HCT patients with resistant or refractory CMV infection.

Credit Expired

Target Audience

Transplantation, infectious disease, and oncology clinicians who manage patients with CMV infection after hematopoietic cell transplant.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ clinical decision support tool recommendations and current guidelines for the treatment of refractory cytomegalovirus (CMV) infection after transplantation
  • Identify risk factors for the development of refractory and drug resistant CMV after transplantation
  • Select treatment for refractory and drug resistant CMV after transplantation based on key data for recently approved therapies
  • Manage potential adverse effects associated with antiviral therapies for CMV

Activity Faculty

Camille Kotton portrait 2021

Camille Nelson Kotton, MD, FIDSA, FAST

Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Chemaly 500x500

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ

Professor, Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research Program
UT MD Anderson Cancer Center
Houston, TX

Genovefa Papanicolaou, MD

Genovefa Papanicolaou, MD

Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor, Medicine
Weill Cornell Medical College, Cornell University
New York, NY


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources